Integration of P2Y receptor-activated signal transduction pathways in G protein-dependent signalling networks

被引:56
作者
Kolen K. [1 ,2 ]
Slegers H. [1 ]
机构
[1] Department of Biomedical Sciences, Cellular Biochemistry, University of Antwerp, 2610 Wilrijk-Antwerpen
[2] CNS Research, Johnson and Johnson, PRD, Janssen Pharmaceutica, Beerse
关键词
C6; glioma; ERK; P2Y receptors; PKB; Transactivation; Tyrosine kinases;
D O I
10.1007/s11302-006-9008-0
中图分类号
学科分类号
摘要
The role of nucleotides in intracellular energy provision and nucleic acid synthesis has been known for a long time. In the past decade, evidence has been presented that, in addition to these functions, nucleotides are also autocrine and paracrine messenger molecules that initiate and regulate a large number of biological processes. The actions of extracellular nucleotides are mediated by ionotropic P2X and metabotropic P2Y receptors, while hydrolysis by ecto-enzymes modulates the initial signal. An increasing number of studies have been performed to obtain information on the signal transduction pathways activated by nucleotide receptors. The development of specific and stable purinergic receptor agonists and antagonists with therapeutical potential largely contributed to the identification of receptors responsible for nucleotide-activated pathways. This article reviews the signal transduction pathways activated by P2Y receptors, the involved second messenger systems, GTPases and protein kinases, as well as recent findings concerning P2Y receptor signalling in C6 glioma cells. Besides vertical signal transduction, lateral cross-talks with pathways activated by other G protein-coupled receptors and growth factor receptors are discussed. © Springer Science + Business Media B.V. 2006.
引用
收藏
页码:451 / 469
页数:18
相关论文
共 151 条
[1]  
Drury A.N., Szent-Gyorgyi A., The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart, J Physiol, 68, pp. 213-237, (1929)
[2]  
Abbracchio M.P., Saffrey M.J., Hopker V., Burnstock G., Modulation of astroglial cell proliferation by analogues of adenosine and ATP in primary cultures of rat striatum, Neuroscience, 59, pp. 67-76, (1994)
[3]  
Burnstock G., Williams M., P2 purinergic receptors: Modulation of cell function and therapeutic potential, J Pharmacol Exp Ther, 295, pp. 862-869, (2000)
[4]  
Burnstock G., Physiological and pathological roles of purines: An update, Drug Dev Res, 28, pp. 195-206, (1993)
[5]  
Ralevic V., Burnstock G., Receptors for purines and pyrimidines, Pharmacol Rev, 50, pp. 413-492, (1998)
[6]  
Burnstock G., Kennedy C., Is there a basis for distinguishing two types of P2-purinoceptors?, Gen Pharmacol, 16, pp. 433-440, (1985)
[7]  
Abbracchio M.P., Burnstock G., Purinoceptors: Are there families of P2X and P2Y purinoceptors?, Pharmacol Ther, 64, pp. 445-475, (1994)
[8]  
Fredholm B.B., Abbracchio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., Williams M., Nomenclature and classification of purinoceptors, Pharmacol Rev, 46, pp. 143-156, (1994)
[9]  
Abbracchio M.P., Boeynaems J.M., Barnard E.A., Boyer J.L., Kennedy C., Miras-Portugal M.T., King B.F., Gachet C., Jacobson K.A., Weisman G.A., Burnstock G., Characterization of the UDP-glucose receptor (re-named here the P2Y<sub>14</sub> receptor) adds diversity to the P2Y receptor family, Trends Pharmacol Sci, 24, pp. 52-55, (2003)
[10]  
Communi D., Gonzalez N.S., Detheux M., Brezillon S., Lannoy V., Parmentier M., Boeynaems J.M., Identification of a novel human ADP receptor coupled to G<sub>i</sub>, J Biol Chem, 276, pp. 41479-41485, (2001)